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Abstract Adenosine represents a powerful modulating fac-
tor, which has been shown to orchestrate the scope, duration,
and remission of the inflammatory response through the acti-
vation of four specific receptors, classified as A1, A2A, A2B,
and A3, all being widely expressed in a variety of immune
cells. Several selective A2A receptor agonists have displayed
anti-inflammatory effects, through the suppression of IL-12,
TNF, and IFN-γ production by monocytes and lymphocytes,
in the setting of chronic intestinal inflammation. However, the
therapeutic application of A2A receptor agonists remains hin-
dered by the risk of serious cardiovascular adverse effects
arising from the wide systemic distribution of A2A receptors.
The present study focused on evaluating the anti-
inflammatory effects of the novel poorly absorbed A2A recep-
tor agonist PSB-0777 in a rat model of oxazolone-induced
colitis as well as to evaluate its cardiovascular adverse effects,
paying particular attention to the onset of hypotension, one of
the main adverse effects associated with the systemic
pharmacological activation of A2A receptors. Colitis was as-
sociated with decreased body weight, an enhancedmicroscop-
ic damage score and increased levels of colonic
myeloperoxidase (MPO). PSB-0777, but not dexamethasone,
improved body weight. PSB-0777 and dexamethasone ame-
liorated microscopic indexes of inflammation and reduced
MPO levels. The beneficial effects of PSB-0777 on inflam-
matory parameters were prevented by the pharmacological
blockade of A2A receptors. No adverse cardiovascular events
were observed upon PSB-0777 administration. The novel A2A
receptor agonist PSB-0777 could represent the base for the
development of innovative pharmacological entities able to
act in an event-specific and site-specific manner.
Keywords A2A adenosine receptor . Colon . Colitis .
Inflammation . Locally acting agent
Introduction
Inflammatory bowel diseases (IBDs) are chronic, idiopathic
inflammatory disorders characterized by alternating periods of
active disease or flare-ups and remission, with highly negative
impact on well-being and patient’s quality of life [1].
Although the precise etiological factors leading to the onset
of these chronic inflammatory conditions remain unclear, in-
creasing evidence supports the concept that IBDs arise from
altered and complex interactions of environmental, genetic,
and immunological factors [2].
At present, an increasing interest is being focused on the
pharmacological modulation of endogenous mediators, ac-
tively involved in the suppression and/or resolution of inflam-
mation, as viable and innovative anti-inflammatory strategies
[3]. On these bases, a number of novel anti-inflammatory and
healing mediators have been identified. Among them,
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adenosine represents a powerful modulating factor, which has
been shown to orchestrate the goal, duration, and remission of
the inflammatory response through the activation of four spe-
cific receptors, classified as A1, A2A, A2B, and A3, all being
widely expressed in a variety of immune cells (lymphocytes,
neutrophils, monocytes, macrophages, and dendritic cells)
[4–6]. On this ground, a number of preclinical and clinical
investigations have been implemented to evaluate the poten-
tial beneficial effects of adenosine receptor ligands in the man-
agement of several inflammatory conditions (i.e., asthma,
chronic obstructive pulmonary disorder, rheumatoid arthritis,
psoriasis, sepsis, IBD), with fairly encouraging results [7–10].
Several selective A2A receptor agonists have displayed
anti-inflammatory effects, through the suppression of IL-
12, TNF, and IFN-γ production by monocytes and lym-
phocytes [11–13], in the setting of chronic intestinal in-
flammation [14, 15], thus supporting a possible employ of
these drugs as novel tools for the management of IBDs.
However, the therapeutic application of A2A receptor ag-
onists remains hindered by the risk of serious cardiovas-
cular adverse effects arising from the wide systemic dis-
tribution of A2A receptors [10]. For these reasons, inten-
sive efforts are being focused on the design of novel ag-
onists aimed at channeling the A2A-mediated anti-inflam-
matory/immunomodulatory effects specifically towards
the inflammatory environment. Along this line, interesting
results have been recently pursued by Müller and co-
workers [16] through the development of PSB-0777, a
novel highly polar A2A-selective agonist, which cannot
be absorbed systemically by the digestive mucosa once
administered by the oral route.
Based on the above background, the present study
has been conceived to investigate the anti-inflammatory
effects of PSB-0777 in a rat model of oxazolone-
induced colitis as well as to evaluate its cardiovascular
effects, paying particular attention to the onset of hypo-
tension, one of the main adverse events associated with
the systemic pharmacological activation of A2A
receptors.
Materials and methods
Stability of PSB-0777 in simulated gastric acid
Preparation of simulated gastric acid
Pepsin 3.2 g (pig, 35,000, i.e., activity), 2.0 g NaCl, and
80 ml HCl (1 M) were mixed together, and pure water
was added to a final volume of 1000 ml (pH = 1.2).
Freshly prepared solutions of the test drugs were used
for the measurements.
Liquid chromatography/mass spectrometry (LC/MS)
measurements
Mass spectra were recorded on an API 2000 (Applied
Biosystems, Darmstadt, Germany) mass spectrometer (turbo
ion spray ion source) coupled with an Agilent 1100 HPLC
system (Agilent, Böblingen, Germany) using a C18 column
from Macherey & Nagel. Solution of PSB-0777 (1 mM) was
added to the simulated gastric acid solution and incubated at
37 °C in a water bath. At specific time intervals of 10, 30, 60,
120, and 180min, 100 μl of the solution were transferred to an
autosampler vial and LC/MS analysis was immediately
started. After 10 min of column equilibration with 90%
H2O/10% MeOH (containing 2 mM ammonium acetate),
8 μl of the samples was injected to the LCMS instrument
and chromatographed at a flow rate of 250 μl/min. A solvent
gradient from 90% H2O/10% MeOH (containing 2 mM am-
monium acetate) to 100%MeOH (containing 2 mM ammoni-
um acetate) was applied within 10 min. The column was sub-
sequently rinsed for 10 min with 100% methanol. Full scan
mass spectra from 150 to 600 μwere recorded in both positive
and negative modes.
Determination of solubility and Caco-2 cell membrane
permeability
These studies were performed by Pharmacelsus, Saarbrücken,
Germany.
Water solubility
Semi-thermodynamic solubility was determined by the shak-
ing flask method. In brief, PSB-0777 was dissolved in DMSO
at a concentration of 20 mM. This stock solution was used to
spike three tubes containing PBS (cutoff concentration
200 μM) with a final solvent content of 1% DMSO. Tubes
were shaken for 24 h, undissolved particles were removed by
centrifugation, and the supernatant was used for quantification
by LC/MS using a 5–8-point calibration curve.
Caco-2 permeability
In order to predict peroral absorption, bidirectional permeation
studies using Caco-2 cells were performed. Caco-2 cells were
differentiated for 21 days in Transwell® plates, and PSB-0777
was tested at a concentration of 10 μM.
Animals
Albino male Sprague-Dawley rats, 200 g body weight, were
used throughout the study. The animals were fed with standard
laboratory chow and tap water ad libitum and were not
employed for at least 1 week after their delivery to the
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laboratory. They were housed, three in a cage, in a
temperature-controlled rooms on a 12-h light cycle at 22–
24 °C and 50–60% humidity. Their care and handling were
in accordance with the provisions of the European
Community Council Directive 210/63/UE, recognized and
adopted by the Italian Government. The experiments were
approved by the Ethica l Commit tee for Animal
Experimentation of the University of Pisa and by the Italian
Ministry of Health.
Induction of colitis, drug treatments, and experimental
design
Colitis was induced in accordance with Ekstrom [17]. Briefly,
during slight inhalation anesthesia with isoflurane, the animals
underwent immune sensitization by painting 0.3 ml acetone/
95% ethanol (1:4), containing 12 mg of oxazolone, on an 8-
cm2 area of shaved abdomen on days 6 and 7 before chal-
lenge. Some animals, to be employed as controls for the sen-
sitization procedure, were painted with the vehicle (acetone/
ethanol) only. Six days after the second sensitization, the an-
imals were challenged with oxazolone injected directly into
the colon. For this purpose, under isoflurane anesthesia, a
rubber catheter was inserted 8 cm into the colon via rectal
route, and 200 ml of the challenge solution was injected.
The challenge solution consisted of 6 mg oxazolone in a mix-
ture consisting of equal parts of carmellose sodium and olive
oil. Carmellose sodium was mixed with olive oil to emulsify
oxazolone. Some animals were treated with carmellose
sodium/olive oil, only as controls, to determine the putative
proinflammatory properties of the vehicle. Test drugs were
administered orally for 6 days starting 2 days before
intracolonic injection of oxazolone (Fig. 1).
A series of preliminary experiments were performed to
select appropriate doses of PSB-0777 (perorally non-
absorbable A2A-selective agonist) (Fig. 2). The dose of dexa-
methasone, employed as a standard anti-inflammatory com-
parator, was selected on the basis of a previous study per-
formed on a rat model of colitis [18].
The first part of the study was aimed at testing the efficacy
of the oral administration of agonist PSB-0777 (0.4 mg/kg/
day) and dexamethasone (1 mg/kg/day) in ameliorating
oxazolone-induced colitis. For this purpose, the effects of test
drugs were evaluated on systemic (body weight) and tissue
[microscopic score, myeloperoxidase (MPO) levels] inflam-
matory parameters. At the time of sacrifice, specimens of co-
lonic tissues were fixed in cold 4% paraformaldehyde for the
assessment of microscopic damage score or immediately
snap-frozen in liquid nitrogen and stored at − 80 °C for sub-
sequent MPO assays. In addition, in order to verify the selec-
tivity of action on A2A receptors, the effects of PSB-0777 on
the inflammatory parameters were evaluated either in the ab-
sence or in the presence of CSC, a selective A2A adenosine
receptor antagonist (1 mg/kg/day). An effective and selective
dose of the receptor antagonist was chosen on the basis of
previous reports [19, 20].
Assessment of colitis
At the end of treatments, colonic tissues were excised, rinsed
with saline, and scored for histological damage, in accordance
with the criteria reported previously by Zhang et al. [21].
Histological evaluations were carried out by light microscopy
on hematoxylin- and eosin-stained sections obtained from
whole-gut specimens fixed in cold 4% neutral formalin, dilut-
ed in phosphate-buffered saline (PBS). Histological score in-
cluded the following criteria: mucosal architecture loss (0–3),
cellular infiltrate (0–3), muscle thickening (0–3), crypt abscess
(0, absent; 1, present), and goblet cell depletion (0, absent; 1,
present). All parameters of histological changes were recorded
and scored for each rat by two observers blinded to treatments.
Assay of tissue myeloperoxidase
Myeloperoxidase (MPO) levels in colonic tissues were deter-
mined as previously reported by Antonioli et al. [22] and
assumed as a quantitative index to estimate the degree of mu-
cosal infiltration by polymorphonuclear cells. Briefly, colonic
Fig. 1 Diagram showing the design and time course of experiments on
rats with oxazolone-induced colitis
Fig. 2 Chemical structure of PSB-0777
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tissue samples (300 mg) were homogenized three times (30 s
each) at 4 °C with a polytron homogenizer (Cole Parmer
Homogenizer, Vernon Hills, IL, USA) in 1 ml of ice-cold
50 mmol/L phosphate buffer (pH 6.0), containing 0.5% of
hexadecyltrimethylammonium bromide to prevent the
pseudoperoxidase activity of hemoglobin as well as to solubi-
lize membrane-bound MPO. The homogenate was sonicated
for 10 s, frozen-thawed three times and spun by centrifugation
for 20 min at 18,000×g. The supernatant was then recovered
and used for determination of MPO by means of a kit for
enzyme-linked immunosorbent assay (Bioxytech, Oxis
International Inc., Portland, OR, USA). All samples were
assayed within 2 days from collection. The results were
expressed as nanograms of MPO per 100 mg of tissue.
Evaluation of tissue TNF levels
TNF levels in colonic tissues were measured by an ELISA kit
(Abcam), as previously described [1]. For this purpose, colon-
ic tissue samples, stored previously at − 80 °C, were weighed,
thawed, and homogenized in 0.4 ml of pH 7.2 PBS/20 mg of
tissue at 4 °C and centrifuged at 10,000×g for 5 min. Aliquots
(100 μl) of the supernatants were then used for assay. Tissue
TNF levels were expressed as picograms per milligram of
tissue.
Evaluation of the systemic effects and plasma
concentrations of test drugs
A second set of experiments was aimed at evaluating putative
correlations between the effects of PSB-0777 on blood pres-
sure and its plasma concentration, after its administration at
doses displaying beneficial effects on oxazolone-induced co-
litis. For this purpose, a subgroup of animals was treated with
test drugs by oral gavage or intraperitoneal route. Systolic
blood pressure was measured before euthanization (30, 60,
120, and 240 min after test drug administration) by the tail-
cuff method at baseline and after injection of experimental
drugs or vehicle (BP recorder 58600; Ugo Basile, Comerio,
Italy). An average of three pressure readings was obtained. At
the time of sacrifice, blood samples were collected in order to
evaluate plasma concentrations of test drugs as described
below.
Assay of test drugs in plasma samples by LC-MS
Pre-treatment of plasma samples Acetonitrile (LCMS qual-
ity) was added to each plasma sample (1:1). Samples were
mixed with a vortexer for 30 s and subsequently sonicated in
an ultrasonic bath for 5 min followed by centrifugation
(Savant SpeedVac, SPD111V) for 10 min. In order to obtain
more concentrated samples, 700 μl from the above samples
was vacuum-dried (40 °C, 3 h, 200 mbar; Savant SpeedVac,
SPD111V). The resulting residues were dissolved in 70 μl
acetonitrile/water (1:1) and centrifuged. The viscous superna-
tants were subsequently diluted with acetonitrile (1:1), ho-
mogenized, and transferred to an LC/MS auto sampler vials
and subjected to quantitative analysis.
Quantitative analyses Mass spectra were recorded on a
micrOTOF-Q mass spectrometer (Bruker) with an
electrospray ionization source coupled with an HPLC
Dionex Ultimate 3000 instrument (Thermo Scientific) using
an EC50/2 Nucleodur C18 Gravity 3-μm column (Macherey-
Nagel). The column temperature was 25 °C. Samples (5 μl)
were injected and a flow rate of 0.3 ml/min was applied.
HPLC analysis started with 90%water containing 0.1% acetic
acid for 1 min, and a gradient was applied after 1 min reaching
100% acetonitrile (containing 0.1% acetic acid) after 10 min.
The column was further flushed with 100% acetonitrile con-
taining 0.1% acetic acid for 5 min. Positive full scan MS was
set and recorded from 50 to 1000m/z (optimized for the target
mass 261.181). For identification and quantification, the ex-
tract ion chromatogram (EIC) of 261.181 ± 0.005% m/z was
used. The employed acetonitrile was of LCMS quality from
Riedel de Haen (Seelze, Germany). The retention time (RT)
was 3.8 min. The limit of detection for PSB-0777 was 1 nM.
Drugs and reagents
Acetonitrile, of LCMS quality, was purchased from Riedel de
Haen (Seelze, Germany). Water was purified by a PURELAB
flex 2 from Veolia water, Celle, Germany. Ammonium ace-
tate, acetic acid, acetone, carmellose sodium, dexamethasone,
ethanol, formalin, hexadecyltrimethylammonium bromide,
and 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one
(oxazolone) pepsin were purchased from Sigma Chemicals
( S a i n t Lo u i s , MO , USA ) . CSC ( (E ) - 8 - [ 2 - ( 3 -
Chlorophenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-1H-pu-
rine-2,6-dione) was purchased from Tocris (Bristol, UK).
The synthesis of PSB-0777 was performed as previously
reported by El Tayeb et al. [16]. For oral gavage administra-
tion, PSB-0777 and dexamethasone were suspended in 1%
methocel (Sigma Chemicals, Saint Louis, MO, USA) and ad-
ministered in a volume of 0.5 ml per rat. For i.p. administra-
tion, test drugs were dissolved in sterile dimethyl sulfoxide
(Sigma Chemicals, Saint Louis, MO, USA).
Statistical analysis
The results are given as mean ± S.E.M. The statistical signif-
icance of differences was assessed by one-way analysis of
variance followed by post hoc analysis by Student-Newman-
Keuls test, and p values lower than 0.05 were considered
significant. All statistical procedures were performed using
Prism 3.0 software (GraphPad, San Diego, CA).
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Results
Solubility, stability, and Caco-2 permeability of PSB-0777
Semi-thermodynamic solubility measurements showed that
PSB-0777 is well soluble in phosphate-buffered saline con-
taining 1% of DMSO, displaying a solubil i ty of
95.3 ± 5.5 μM. Moreover, PSB-0777 displayed high stability
in simulated gastric acid at 37 °C for at least 3 h. No degrada-
tion was observed (data not shown). Caco-2 cell transport
assays indicated no penetration (data not shown).
Evaluation of anti-inflammatory effects
Body weight
Rats with oxazolone-induced colitis displayed a lower body
weight gain as compared with control animals (Fig. 3).
Significant increments of body weight were observed in rats
with colitis under treatment with PSB-0777 (Fig. 3): These
effects were significantly counteracted by CSC (Fig. 3). By
contrast, a significant body weight loss was recorded after
administration of dexamethasone (Fig. 3). This effect was
not altered by co-administration of dexamethasone with
CSC (not shown).
Colonic microscopic damage score
Histological examination of colonic specimens from
oxazolone-treated rats showed the presence of an inflamma-
tory reaction at the colonic level, characterized by disruption
of the epithelial layer and lamina propria, accompanied by
mucosal edema, infiltration by inflammatory cells into the
mucosa, along with goblet cell disruption and disappearance
(Fig. 4b), as compared with colonic specimens from control
rats (Fig. 4a). Colonic sections from rats with colitis displayed
a marked increase in microscopic damage score (Fig. 5). In
colonic tissues from inflamed animals treated with PSB-0777
or dexamethasone, a marked reduction of inflammatory cell
infiltration and an amelioration of colonic mucosal architec-
ture were found (Fig. 4c, d), with a consequent improvement
of the microscopic damage score (Fig. 5). The effect of PSB-
0777 was significantly counteracted the administration of the
A2A antagonist CSC (Fig. 5). No significant alteration was
observed in the beneficial effects of dexamethasone upon
co-administration with CSC (not shown).
Colonic tissue myeloperoxidase levels
Oxazolone-treated rats displayed a marked increase in colonic
MPO levels, as compared with control animals (Fig. 6).
Treatment with PSB-0777 counteracted significantly the in-
crement of colonic MPO levels associated with colitis (Fig. 6).
A significant decrease in MPO levels was also obtained fol-
lowing treatment with dexamethasone (Fig. 6). The effects of
PSB-0777 on colonic MPO levels were blunted by the A2A
receptor antagonist CSC (Fig. 6), whereas no significant ef-
fects were observed upon co-treatment with dexamethasone
(not shown).
Colonic tissue TNF levels
Colonic inflammation induced by oxazolone was associated
with a significant increase in tissue TNF levels (Fig. 6b).
Treatments with PSB-0777 significantly decreased the con-
centration of this cytokine in colonic tissues (Fig. 6b).
Dexamethasone-treated animals showed a significant de-
crease in TNF colonic tissue levels (Fig. 6b). The A2A receptor
antagonist CSC prevented the effects of PSB-0777 (Fig. 6b)
but was ineffective on the effect of dexamethasone (not
shown).
Plasma concentrations
Only very low plasma concentrations of PSB-0777 in peroral-
ly treated rats were detectable at 30 min (below 5 nM), but not
60 min after administration, indicating a very low systemic
absorption by the oral route (limit of detection 1 nM)
(Fig. 7a). This compound was not detectable in plasma sam-
ples 60 min after its administration (Fig. 7a). After i.p admin-
istration, PSB-0777 plasma concentrations were well evident
at 30 min, decreased after 60 min, and were not detectable at
120 and 240 min (Fig. 7a).
Fig. 3 Effects of PSB-0777 (0.4 mg/kg/day) alone or in combination
with CSC (1 mg/kg/day) or dexamethasone (1 mg/kg/day) on body
weight in rats with oxazolone-induced colitis. Each column represents
the mean ± S.E.M (n = 6). *p < 0.05, significant difference versus control
group; ap < 0.05, significant difference versus oxazolone group
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Systolic blood pressure evaluation
Rats treated perorally with PSB-0777 did not show any
significant variation of systolic blood pressure as compared
with control animals (Fig. 7b). By contrast, in rats treated
intraperitoneally (i.p.) with PSB-0777, the systolic blood
pressure significantly decreased after 30 and 60 min, but
not after 120 and 240 min, of treatment, as compared to
control (Fig. 7b). Of note, the hypotensive effect of PSB-
0777 after i.p. administration was prevented by the admin-
istration of the A2A receptor antagonist (data not shown).
Discussion
It is being increasingly appreciated that adenosine holds a
crucial role in the modulation of inflammatory and immune
responses, thus spurring the progress of medicinal chemistry
towards the development of novel compounds acting on this
pathway, as promising pharmacological entities against intes-
tinal inflammatory disorders [10]. In this context, compelling
evidence supports A2A receptors as the major immunoregula-
tory arm of the adenosine system [10]. For this reason, con-
sistent efforts are being dedicated to the development of A2A
receptor agonists for the therapeutic management of several
inflammatory disorders, such as asthma [23, 24], arthritis [25,
26], glomerulonephritis [27, 28], sepsis [29, 30], and intestinal
inflammation [14, 31, 32]. However, the great expectation
about the therapeutic use of A2A receptor agonists as a viable
anti-inflammatory strategy is being challenged by several con-
cerns, mainly depending on their severe hypotensive effects
related to the wide distribution of A2A receptors in the cardio-
vascular system [33].
Based on the above background, the present study was
performed as follows: (i) to investigate, by means of in vitro
experiments, the stability of PSB-0777 (a novel A2A receptor
agonist conceived to act as a poorly absorbed locally acting
compound) in simulated gastric acid fluid as well as its cell
membrane permeability; (ii) to evaluate the potential anti-
inflammatory effects of PSB-0777 in a rat model of colitis;
Fig. 4 Hematoxylin and eosin-
stained sections of rat colon.
Microscopic images refer to
control rats (a) or oxazolone-
treated animals, either alone (b) or
in the presence of PSB-0777
(0.4 mg/kg/day) (c) or
dexamethasone (1 mg/kg/day) (d)
Fig. 5 Microscopic damage scores estimated for colon in rats under
normal conditions or after oxazolone treatment, either alone or in the
presence of PSB-0777 (0.4 mg/kg/day) alone or in combination with
CSC (1 mg/kg/day), or dexamethasone (1 mg/kg/day) administration.
Each column represents the mean S.E.M. (n = 6). *p < 0.05, significant
difference versus control group; ap < 0.05, significant difference versus
oxazolone group
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and (iii) to assess the impact of this ligand on blood pressure
following its oral administration.
The first set of experiments allowed to demonstrate a sig-
nificant stability of PSB-0777 in an in vitro gastric simulated
environment, indicating the suitability of the oral administra-
tion of this compound. In parallel, experiments performed on
CaCo-2 cell monolayers, aimed at investigating the level of
PSB-0777 penetration, displayed a lack of absorption of this
A2A agonist. This evidence is consistent with the chemical
properties of PSB-0777 [16]. Indeed, as reported by El-
Tayeb et al. [16], this compound, besides being endowed with
high affinity for A2A receptors and high selectivity (> 225-
fold) over the other adenosine receptors, is endowed with a
high polar structure, which confers to the compound high
solubility in water and a lack of permeability across cell mem-
branes. These physico-chemical features of PSB-0777 ac-
count for its scarce systemic bioavailability upon oral
administration, as documented by our in vivo experiments.
On these bases, PSB-0777 may represent a useful candidate
for exerting a local anti-inflammatory action on bowel muco-
sa, while sparing a concomitant decrease in the risk of hypo-
tension and other systemic adverse effects.
Following the above positive findings, we decide on going
with the second set of experiments to evaluate the putative
anti-inflammatory effects of PSB-0777 in the experimental
model of oxazolone-induced colitis. This model is regarded
as remnant of ulcerative colitis, characterized by weight loss,
diarrhea, loss of epithelial cells, erosion of the mucosal layer,
ulcers, decrease in goblet cell number and gland density, and
pronounced MPO tissue activity [17, 21]. In particular, the
inflammatory process develops in or beneath the epithelial
mucosa layer, although in some cases the muscle layer too
appears to be infiltrated by immune/inflammatory cells [17,
21]. In our hands, the suitability of this model was demon-
strated by the ability of dexamethasone to ameliorate the his-
tological colonic damage as well as to reduce tissue TNF and
MPO levels, in line with previous reports showing similar
beneficial effects of this glucocorticoid drug [34]. When con-
sidering the effects of PSB-0777 on body weight, microscopic
damage score, and tissue TNF and MPO levels, as an index of
inflammatory cell infiltrate, we observed an amelioration of
all these inflammatory parameters. In particular, animals treat-
ed with PSB-0777 displayed a significant increase in body
weight gain as well as an improvement of the histological
damage score and a decrease in TNF and MPO levels, thus
providing additional evidence that the pharmacological stim-
ulation of A2A receptors at inflammatory sites can result in a
significant attenuation of the phlogistic processes [15, 35, 36].
The increase in bodyweight resulted very likely from the local
action of PSB-0777 in the intestine, since the systemic admin-
istration of PSB-0777 was previously found to lead to a de-
crease in body weight in mice fed with high-fat diet due to the
activation of A2A adenosine receptors in adipocytes [37].
A2A receptors, widely expressed on innate and adaptive
immune cells [38], have been shown to curb their activity,
thus reducing their cytotoxic functions, adhesion, production
of oxygen radicals, degranulation, and release of proinflam-
matory cytokines (i.e., TNF, IL-1β, IL-6, IL-12, IL-17) as
well as counteracting the activation of nuclear factor
(NF)-κB [39]. Of note, neutrophils are a critical source of
adenosine [40]. Indeed, once activated, these cells release
massively ATP via connexin 43 hemichannels, which is
quickly converted into AMP and adenosine by the
ectoenzymes CD39 and CD73, respectively, expressed on
the neutrophil surface [40]. The activation of A2A receptors
expressed on neutrophils can influence the broader inflamma-
tory response by modulating production and release of pro-
and anti-inflammatory mediators, such as chemokines, leuko-
trienes, and prostaglandins [40], pointing out a critical role for
this receptor subtype in shaping the immune response.
Fig. 6 aMPO and b TNF levels in colonic tissues from control rats or in
animals treated with oxazolone, either alone or in combination with PSB-
0777 (0.4 mg/kg/day) alone or in combination with CSC (1 mg/kg/day),
or dexamethasone (1 mg/kg/day). Each column represents the mean
S.E.M. (n = 6). *p < 0.05, significant difference versus control group;
ap < 0.05, significant difference versus oxazolone group
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The beneficial effects of A2A receptor agonists have been
documented in several models of bowel inflammation, where
A2A activation was found to prevent the trafficking of immune
cells into the enteric mucosa [14]. In these models, consistent-
ly with our results, the decrease in leukocyte infiltration fol-
lowing A2A receptor stimulation was associated with a signif-
icant amelioration of the disease course, as indicated also by
the preservation of mucosal architecture and villi [14]. In a
recent paper, El Tayeb et al. [16], by means of in vitro studies,
documented the efficacy of PSB-0777 in reverting the alter-
ations of acetylcholine-induced contractions in the presence of
intestinal inflammation induced via incubation of ileal tissues
with 2,4,6-trinitrobenzenesulfonic acid colitis, thus strength-
ening the hypothesis about the potential usefulness of this
non-absorbable A2A-selective agonist to counteract enteric
motor dysfunctions associated with bowel inflammation. In
the present study, we have shown, for the first time, that a
highly polar A2A receptor agonist, which penetrates poorly
cell membranes, exerted a significant effect in a model of
colitis. In this regard, it is noteworthy that the murine model
of oxazolone-induced colitis, as observed also in UC patients,
is characterized by a laxity of epithelial tight junctions leading
to an increase in mucosal permeability [41–43]. In particular,
a pivotal role of NK cells in the alteration of epithelial
layer, which may contribute significantly to the onset and
development of oxazolone-induced colitis, has been re-
ported [43]. Thus, based on this body of evidence, it is
conceivable that the inflammatory impairments of the en-
teric mucosal barrier allow PSB-0777 to reach the lamina
propria, where it can exert its immunomodulatory effects,
without acting at a systemic level. In this context, the
relevant role of A2A adenosine receptors in mediating
the deep immunosuppressive actions of adenosine on sev-
eral immune cell populations, including NK cells, is wide-
ly recognized [6, 39].
These observations might pave the way to the clinical de-
velopment of non-absorbable A2A antagonists also for treat-
ment of other intestinal disorders, such as the irritable bowel
syndrome, characterized by alterations of the enteric epithelial
barrier [44].
As anticipated above, systemically acting A2A receptor
agonists can exert remarkable hemodynamic effects, which
so far have severely limited their development for therapeu-
tic employment, as anti-inflammatory drugs [26]. For this
reason, the second part of the present study was aimed at
evaluating plasma concentrations of PSB-0777, to verify its
systemic bioavailability and to investigate its putative ef-
fects on blood pressure. As expected, our findings
displayed a lack of significant systemic absorption of
PSB-0777 after oral administration, thus indicating a neg-
ligible bioavailability by this route. By contrast, following
its intraperitoneal administration, the compound could be
detected in plasma samples at concentrations that are ex-
pected to activate A2A receptors. Of note, these pharmaco-
kinetic features are in line with a lack of systemic effects by
PSB-0777 following its oral administration. Indeed, ani-
mals treated perorally with PSB-0777 did not show any
significant variation of systolic blood pressure, at variance
with rats treated intraperitoneally with this compound,
displaying a significant decrease in systolic blood pressure.
In addition, the selective A2A antagonist CSC prevented the
PSB-0777-induced hypotensive effect after intraperitoneal
administration, thus corroborating further the evidence that
this effect resulted from the activation of A2A receptors.
Fig. 7 a Plasma concentration of
PSB-0777 (0.4 mg/kg/day) 30,
60, 120, and 240 min after oral or
intraperitoneal administration in
rats with oxazolone-induced
colitis. b Effects of PSB-
0777(0.4 mg/kg/day) 30, 60, 120,
240 min after oral or
intraperitoneal administration on
systolic blood pressure in rats
with oxazolone-induced colitis.
Each column represents the mean
S.E.M. (n = 6). *p < 0.05,
significant difference versus
vehicle-treated animals
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Our data about the efficacy of PSB-0777 in
counteracting colonic inflammation, in parallel with a
very low systemic bioavailability of PSB, provide suffi-
cient, although indirect, demonstration that, upon oral
administration, PSB achieves local concentrations in
the intestinal lumen that were fairly sufficient to coun-
teract mucosal inflammation. However, the lack of a
direct evaluation about the concentration achieved by
PSB in the luminal content represents a point of limita-
tion of the present study that need to be resolved in
future studies.
In conclusion, there is no question that the field of
drugs acting on the adenosine pathway represents a huge
opportunity for the development of novel anti-inflamma-
tory/immunomodulatory agents. In particular, the passion-
ate interest currently revolving around the adenosine sys-
tem points out the discovery of several innovative mole-
cules, for which the performance of preclinical and clini-
cal studies is needed to define and understand their puta-
tive value in the management of immune/inflammatory
disorders [10]. In this context, the novel locally acting
A2A receptor agonist PSB-0777 could represent the base
for the development of innovative pharmacological enti-
ties able to act both in an event-specific and site-specific
manner, thus harnessing the beneficial effects arising from
the stimulation of A2A receptors, without the limitation of
adverse effects associated with the systemic stimulation of
these receptors.
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